Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice.

Abstract

We have investigated the efficacy of immunization against peptides from predisposing MHC class II molecules in human-compatible adjuvants for ameliorating experimental autoimmune myasthenia gravis (EAMG). C57BL/6 mice were immunized three times with the peptide I-Abetab62-76 in Alum+killed pertussis organisms (PT) prior to two injections with tAChR. The treatment greatly reduced the occurrence and severity of clinical MG relative to controls that received saline/Alum+PT or none. It also reduced antibody and T-cell responses against tAChR. The results have important implications for the possible immunotherapy of MG by targeting disease-associated MHC.

• Authors: Minako Oshima, Takahiro Maruta, Maki Ohtani, Philip R Deitiker, Dennisr Mosier, M Zouhair Atassi
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 171 Issue 1-2 Pg. 8-16 (Feb 2006) ISSN: 0165-5728 [Print] Netherlands
• PMID: 16271400 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Alum Compounds
• Antibodies
• Histocompatibility Antigens Class II
• Pertussis Vaccine
• Receptors, Cholinergic
• aluminum sulfate

Topics

• Action Potentials (physiology)
• Alum Compounds
• Animals
• Antibodies (therapeutic use)
• Antibody Formation
• Cell Proliferation (drug effects)
• Disease Models, Animal
• Female
• Histocompatibility Antigens Class II (administration & dosage, immunology)
• Humans
• Lymph Nodes (cytology)
• Lymphocyte Activation
• Mice
• Mice, Inbred C57BL
• Muscle, Skeletal (physiopathology)
• Myasthenia Gravis, Autoimmune, Experimental (immunology, physiopathology, prevention & control)
• Pertussis Vaccine (administration & dosage, immunology)
• Physical Conditioning, Animal (methods)
• Radioimmunoassay (methods)
• Receptors, Cholinergic (immunology)
• Torpedo
• Vaccination (methods)